LivaNova PLC (NASDAQ:LIVN) CFO Thad Allen Huston sold 2,000 shares of LivaNova stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $75.00, for a total value of $150,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link.
LIVN stock opened at $71.94 on Thursday. The firm has a market capitalization of $3.55 billion, a P/E ratio of 22.69, a PEG ratio of 3.17 and a beta of 0.61. The company has a 50-day moving average of $72.62. LivaNova PLC has a 52 week low of $64.80 and a 52 week high of $131.54. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.61 and a current ratio of 0.87.
LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $0.54 EPS for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.11. The business had revenue of $250.80 million during the quarter, compared to the consensus estimate of $254.89 million. LivaNova had a positive return on equity of 9.38% and a negative net margin of 19.64%. LivaNova’s revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.68 earnings per share. As a group, analysts anticipate that LivaNova PLC will post 2.6 EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of LIVN. Norges Bank acquired a new position in LivaNova in the fourth quarter valued at about $46,478,000. JPMorgan Chase & Co. raised its stake in LivaNova by 31.5% during the first quarter. JPMorgan Chase & Co. now owns 647,760 shares of the company’s stock worth $62,995,000 after acquiring an additional 155,079 shares in the last quarter. Gotham Asset Management LLC acquired a new position in LivaNova during the fourth quarter worth about $13,750,000. BlackRock Inc. raised its stake in LivaNova by 2.2% during the fourth quarter. BlackRock Inc. now owns 5,915,599 shares of the company’s stock worth $541,101,000 after acquiring an additional 127,669 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB raised its stake in LivaNova by 99.5% during the first quarter. Rhenman & Partners Asset Management AB now owns 240,600 shares of the company’s stock worth $23,398,000 after acquiring an additional 120,000 shares in the last quarter. 84.37% of the stock is owned by institutional investors and hedge funds.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.